The stock of the French biotech company increased by 2.2% to €3.43 mid-session in a rising Parisian market. The previous day, Kempen maintained its buy recommendation while reducing its price target from €11 to €9. This movement occurred a few days after the publication of the first quarter 2026 results.
Kempen Lowers Target to €9 While Maintaining Buy
Kempen adjusted its opinion on DBV Technologies on May 4. The Dutch firm continues to recommend buying but has lowered its target from €11 to €9. Based on the current price of €3.43, the implied upside potential remains over 160%. This revision follows the quarterly publication on April 30,…
